- AuthorisedPhase II and Phase III (Integrated)
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.
This study is testing a new medicine, Mitapivat, for people with sickle cell disease. It aims to see if the medicine can help increase healthy red blood cells and reduce painful crises. Some people will receive the medicine, and others a dummy pill, to compare effects.
For: Anemia in subjects with sickle cell disease (SCD)Netherlands · Germany · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
This study is checking a new treatment called Immukine alongside usual care for a serious fungal infection in the blood called candidemia. Researchers want to see if it makes people get better faster and how safe it is.
For: CandidemiaNetherlands · Greece · Romania - AuthorisedTherapeutic confirmatory (Phase III)
SABINE - The efficacy and Safety of delayed-release Budesonide in children with primary IgA nephropathy - a multicenter, interventional phase III, randomized, placebo-controlled, double-blind study.
This study looks at a new way to treat a kidney condition called IgA nephropathy in children. It compares a special medicine (budesonide) with a dummy medicine (placebo) to see if it can help reduce protein in the urine and is safe.
For: Children primary nephropathy IgAPoland